GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » 3-Year EPS without NRI Growth Rate

ValiRx (LSE:VAL) 3-Year EPS without NRI Growth Rate : 13.30% (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx 3-Year EPS without NRI Growth Rate?

ValiRx's EPS without NRI for the six months ended in Dec. 2024 was £-0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 13.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 38.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 55.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of ValiRx was 96.00% per year. The lowest was 2.60% per year. And the median was 50.00% per year.


Competitive Comparison of ValiRx's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, ValiRx's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where ValiRx's 3-Year EPS without NRI Growth Rate falls into.


;
;

ValiRx 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


ValiRx  (LSE:VAL) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


ValiRx 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of ValiRx's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.